trending Market Intelligence /marketintelligence/en/news-insights/trending/48cqCDAktha0B20h_yFBRw2 content esgSubNav
In This List

Indivior submits US FDA application for opioid-addiction treatment

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Indivior submits US FDA application for opioid-addiction treatment

Indivior PLC submitted a new drug application to the U.S. FDA for its product candidate, RBP-6000, following a successful phase 3 study.

RBP-6000 is an investigational, once-monthly injectable form of buprenorphine to treat moderate to severe opioid use disorder.